Results 131 to 140 of about 1,063 (182)

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. [PDF]

Prostate Cancer Prostatic Dis
Shore N, Hafron J, Saltzstein D, Bhaumik A, Aggarwal P, Phillips J, McGowan T.   +6 more
europepmc   +1 more source

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. [PDF]

Cancer
Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C, Ravani P, Bossé D, Talarico R, Carrier M, Sood MM.   +10 more
europepmc   +1 more source

The comparison of outcomes between neoadjuvant novel and classical hormonal therapy in patients with locally advanced prostate cancer: a retrospective study. [PDF]

BMC Urol
Yang Z, Liu Y, Shao Y, Wu Y, Wang Y, Guo J, Liu Z, Huang H, Tian J, Niu Y, Wen S.   +10 more
europepmc   +1 more source

Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer. [PDF]

Curr Oncol
Encarnación Navarro JA, Morillo Macías V, Borrás Calbo M, De la Fuente Muñoz I, Lozano Martínez A, García Martínez V, Fernández Fornos L, Guijarro Roche M, Amr Rey O, García Gómez R.   +9 more
europepmc   +1 more source

Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. [PDF]

J Cancer Res Clin Oncol
Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D.   +12 more
europepmc   +1 more source

Integrated DFT, molecular docking, and molecular dynamics investigation of some novel 2-thiohydantoin analogues as potent CDK2 inhibitors for anticancer therapy. [PDF]

Sci Rep
Khaled NA, Ahmed SA, Ibrahim MA, Ahmed OM, Mohamed NA, Khalifa NM.   +5 more
europepmc   +1 more source

The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan). [PDF]

Sci Rep
Shiota M, Liu Y, Mundle S, Nematian-Samani M, Hwang J, Wang X, Uemura H.   +6 more
europepmc   +1 more source

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer. [PDF]

Nat Commun
Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt DE.   +31 more
europepmc   +1 more source

Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials. [PDF]

JAMA Netw Open
Roy S, Ozay ZI, Guha A, Sun Y, Chi KN, Morgan SC, Malone S, Wallis CJD, Brown JR, Barata PC, Kishan AU, Jia AY, Zaorsky NG, Swami U, Chowdhury S, Small EJ, Spratt DE, Saad F, Agarwal N.   +18 more
europepmc   +1 more source

Studies on sequencing of peptides from the carboxyl terminus by using the thiocyanate method [PDF]

A Darbre, M Rangarajan
core   +1 more source